Troleandomycin
Tao (troleandomycin) is a small molecule pharmaceutical. Troleandomycin was first approved as Tao on 1982-01-01. It is used to treat asthma, campylobacter infections, chlamydia infections, gonorrhea, and legionnaires' disease amongst others in the USA. It is known to target cytochrome P450 3A4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
respiratory tract diseases | D012140 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
asthma | EFO_0000270 | D001249 | J45 |
campylobacter infections | EFO_0007190 | D002169 | — |
chlamydia infections | EFO_0007205 | D002690 | A74.9 |
gonorrhea | DOID_7551 | D006069 | A54 |
legionnaires' disease | EFO_0007343 | D007877 | A48.1 |
mycoplasma infections | — | D009175 | — |
staphylococcal infections | — | D013203 | A49.01 |
streptococcal infections | EFO_1001476 | D013290 | — |
syphilis | EFO_0007504 | D013587 | A53.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
149 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | C61 | 1 | 12 | 17 | 6 | 4 | 37 | |
Infertility | D007246 | EFO_0000545 | 1 | 4 | 7 | 17 | 9 | 37 | |
Female infertility | D007247 | EFO_0008560 | N97 | 2 | 2 | 2 | 3 | 3 | 10 |
Endometriosis | D004715 | EFO_0001065 | N80 | 1 | 1 | 3 | 2 | 3 | 9 |
Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | 1 | 1 | 3 | 2 | 7 |
Fertilization in vitro | D005307 | — | — | 1 | 5 | 1 | 7 | ||
Precocious puberty | D011629 | E22.8 | — | — | 6 | 1 | — | 7 | |
Intracytoplasmic sperm injections | D020554 | — | — | — | 4 | — | 4 | ||
Ovarian hyperstimulation syndrome | D016471 | — | — | 1 | 3 | — | 4 | ||
Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 1 | 1 | — | 1 | — | 2 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 5 | 6 | — | — | 11 |
Adenocarcinoma | D000230 | 1 | 2 | 2 | — | — | 4 | ||
Lymphoma | D008223 | C85.9 | — | 2 | 3 | — | — | 3 | |
Male breast neoplasms | D018567 | 1 | 1 | 1 | — | — | 2 | ||
Sarcoma | D012509 | — | 1 | 2 | — | — | 2 | ||
Osteosarcoma | D012516 | — | 1 | 2 | — | — | 2 | ||
Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | 2 | — | — | 2 | |
Bone neoplasms | D001859 | EFO_0003820 | D16 | — | — | 1 | — | — | 1 |
Fertility preservation | D059247 | — | 1 | 1 | — | — | 1 | ||
Neoadjuvant therapy | D020360 | — | 1 | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | 1 | 1 | — | — | — | 1 | |
Leiomyoma | D007889 | HP_0000131 | D25 | 1 | 1 | — | — | — | 1 |
Ectopic pregnancy | D011271 | O00 | 1 | 1 | — | — | — | 1 | |
Salpingitis | D012488 | N70.91 | 1 | 1 | — | — | — | 1 | |
Triple negative breast neoplasms | D064726 | — | 1 | — | — | — | 1 | ||
Drug-related side effects and adverse reactions | D064420 | T88.7 | — | 1 | — | — | — | 1 | |
Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | — | 1 | — | — | — | 1 |
Female urogenital diseases | D052776 | — | 1 | — | — | — | 1 | ||
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TROLEANDOMYCIN |
INN | troleandomycin |
Description | Troleandomycin is a semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug. It has a role as an EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor and a xenobiotic. It is a macrolide antibiotic, a polyketide, a monosaccharide derivative, an epoxide, an acetate ester and a semisynthetic derivative. It is functionally related to an oleandomycin. |
Classification | Small molecule |
Drug class | antibiotics (Streptomyces strain) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O |
Identifiers
PDB | — |
CAS-ID | 2751-09-9 |
RxCUI | 10864 |
ChEMBL ID | CHEMBL564085 |
ChEBI ID | 45735 |
PubChem CID | 202225 |
DrugBank | DB01361 |
UNII ID | C4DZ64560D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CYP3A4
CYP3A4
Organism
Homo sapiens
Gene name
CYP3A4
Gene synonyms
CYP3A3
NCBI Gene ID
Protein name
cytochrome P450 3A4
Protein synonyms
1,4-cineole 2-exo-monooxygenase, 1,8-cineole 2-exo-monooxygenase, Albendazole monooxygenase (sulfoxide-forming), Albendazole sulfoxidase, Cholesterol 25-hydroxylase, CYPIIIA3, CYPIIIA4, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, cytochrome P450, family 3, subfamily A, polypeptide 4, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, Cytochrome P450-PCN1, glucocorticoid-inducible P450, Nifedipine oxidase, P450-III, steroid inducible, Quinine 3-monooxygenase, taurochenodeoxycholate 6-alpha-hydroxylase
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 642 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,606 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more